Sun Pharma Q4 net profit at ₹1,984 crore

Sun Pharmaceutical Industries Ltd. reported that its fourth quarter consolidated net profit grew to ₹1,984.5 crore compared with net loss of ₹2,277.3 crore in the same period last year, due to improved performance.

Sun Pharmaceutical Industries Ltd. reported that its fourth quarter consolidated net profit grew to ₹1,984.5 crore compared with net loss of ₹2,277.3 crore in the same period last year, due to improved performance.

Gross sales at ₹10,725.6 crore grew 14.3% Year on Year (YoY), the company said in a press release.

India formulation sales at ₹3,364.1 crore was up 8.7% YoY and US formulation sales at $430 million was up 10.5% compared with Q4 last year, it said.

Emerging Markets formulation sales at $221 million, was up 7.5% while Rest of World formulation sales at $191 million was up 7.4% YoY, the company added.

For the financial year ended March 31, 2023 the company reported a net profit of ₹8,473.6 crore compared with ₹3,272.7 crore last year.

Gross sales at ₹43,278.9 crore grew 12.6% over the same period last year.

The Board has proposed a final dividend of ₹4 per share for the year FY23. This is in addition to the interim dividend of ₹7.5 per share paid in FY23, taking the total dividend for FY23 to ₹11.5 per share compared to ₹10 per share for FY22.